The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …

Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …

Cancer is one of the leading causes of death worldwide. Several treatments are available for
cancer treatment, but many treatment methods are ineffective against multidrug-resistant …

As crucial antigen presenting cells, dendritic cells (DCs) play a vital role in tumor
immunotherapy. Taking into account the many recent advances in DC biology, we discuss …

Current success of immunotherapy in cancer has drawn attention to the subsets of TH cells
in the tumor which are critical for activation of anti-tumor response either directly by …

At the interface between the innate and adaptive immune system, dendritic cells (DCs) play
key roles in tumour immunity and hold a hitherto unrealized potential for cancer …

Human epidermal growth factor receptor 2–positive (HER2+) breast cancer accounts for~
25% of breast cancer cases. Monoclonal antibodies (mAbs) against HER2 have led to …

Breast cancer has become the most commonly diagnosed cancer globally. The relapse and
metastasis of breast cancer remain a great challenge despite advances in chemotherapy …

Dendritic-cells (DCs) have received considerable attention as potential targets for the
development of anticancer vaccines. DC-based anticancer vaccination relies on patient …

Immunotherapy using checkpoint inhibitors is one of the most promising current cancer
treatment strategies. However, in breast cancer, its success has been limited to a subset of …